A Phase 3 interventional study of Bimekizumab in Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 189 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.
Among the 20 studies testing bimekizumab in Psoriasis, this one has the largest enrollment, is one of 4 that started in 2018, is one of 10 in phase 3, and was the 9th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Canada, China and 10 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–45
University Hospital, Rouen · Sites in France
Ages 18–60
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,353 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 161 across the 20 interventional studies. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 8 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
26 studies in Psoriasis by UCB S.A.: 1 open now, 2 under way, 2 of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 26 studies in Psoriasis by UCB S.A., this one has the largest enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2018, is one of 14 in phase 3, and was the 17th registered.
UCB S.A.’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing bimekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 26 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
The study consists of a 144-week Treatment Period (open-label) and an optional 48-week Open-Label Extension Period 2 (OLE2) for eligible subjects in the USA and Canada.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Treatment Period (open-label)
Female subjects must be:
OLE2 Period (USA and Canada)
Exclusion Criteria:
Treatment Period (open-label)
OLE2 Period (USA and Canada)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects are randomized to receive either dose regimen 1 (BKZ 1) or dose regimen 2 (BKZ 2) during the 144-week Treatment Period (open-label), those on BKZ 1 will switch to BKZ 2 at Week 24 or later (at the next scheduled clinic visit after Week 48) Eligible subjects who completed the Treatment Period (open-label), and have entered Safety Follow Up (SFU) or completed SFU would start OLE2 on BKZ 1 before switching to BKZ 2 after 16 weeks. Intervention Name: Bimekizumab
Drug: Bimekizumab
Subjects are randomized to receive BKZ 2 during the 144-week Treatment Period (open-label). Eligible subjects who completed the Treatment Period (open-label), would continue OLE2 on BKZ 2. Intervention Name: Bimekizumab
Drug: Bimekizumab
Subjects will receive bimekizumab at pre-specified time-points.
Also known as: UCB4940
Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP)
The number of TEAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Time frame: From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to IMP
The number of SAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk is used.
Time frame: From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to IMP
The number of TEAEs leading to withdrawal adjusted by duration of exposure to study treatment were scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Time frame: From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period
Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Non-responder Imputation)
The PASI90 response assessments were based on improvement (reduction) of at least 90% in the PASI score compared to Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
Time frame: Week 144 compared to Baseline of Feeder study for Cohort A and Baseline of PS0014 for Cohort B
Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Observed Case)
PASI90 response assessments were based on improvement (reduction) of at least 90% in the PASI score compared to Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum score is 0= no disease, maximum score is 72= maximal disease.
Time frame: Week 144 compared to Baseline of PS0014 for Cohort B
Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Non-responder Imputation)
The Investigator assessed the overall severity of psoriasis using the following 5-point scale: 0 = Clear (no signs of psoriasis; post-inflammatory hyperpigmentation may be present); 1= Almost clear (no thickening; normal to pink coloration; no to minimal focal scaling); 2= Mild (just detectable to mild thickening; pink to light red coloration; predominately fine scaling); 3= Moderate (clearly distinguishable to moderate thickening; dull to bright red coloration; moderate scaling); 4= Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). IGA response -IGA score of clear \[0\] or almost clear \[1\] with at least two category improvement from Baseline at visit timepoint.
Time frame: Week 144 compared to Baseline of Feeder study for Cohort A and Baseline of PS0014 for Cohort B
Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Observed Case)
The Investigator assessed the overall severity of psoriasis using the following 5-point scale: 0 = Clear (no signs of psoriasis; post-inflammatory hyperpigmentation may be present); 1= Almost clear (no thickening; normal to pink coloration; no to minimal focal scaling); 2= Mild (just detectable to mild thickening; pink to light red coloration; predominately fine scaling); 3= Moderate (clearly distinguishable to moderate thickening; dull to bright red coloration; moderate scaling); 4= Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). IGA response -IGA score of 0 or 1 at Week 144.
Time frame: Week 144 for Cohort B EP and GPP groups
The study started to enroll participants in September 2018 and concluded in November 2023. Participant flow refers to the Cohort A Safety Set, Cohort A OLE2 Period Set and Cohort B Safety Set. Participants who enrolled in PS0014 after completion of Phase 3 feeder studies were included in Cohort A. An additional Cohort B was added in Japan.
| Milestone | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W/Q8W | Cohort A: BKZ 320 mg Q4W | Cohort A: Group A BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q4W/Q8W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total |
|---|---|---|---|---|---|---|---|---|---|
| Started | 384 | 833 | 70 | 0 | 0 | 0 | 45 | 11 | 10 |
| Completed | 326 | 746 | 0 | 0 | 0 | 0 | 38 | 10 | 8 |
| Not completed | 58 | 87 | 70 | 0 | 0 | 0 | 7 | 1 | 2 |
| Withdrew: Adverse event | 24 | 33 | 24 | 0 | 0 | 0 | 3 | 1 | 2 |
| Withdrew: Lack of efficacy | 4 | 7 | 5 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 7 | 11 | 14 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Consent withdrawn by subject | 14 | 26 | 17 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 pandemic circumstances | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Long ip pause; investigator decided termination | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawn by sponsor | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Patient did not comply with safety precautions | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 pandemic circumstances | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor's decision | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Unplanned elective surgery | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Site closure; subject did not want to transfer | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 restrictions; subject unable to return | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject withdraw consent (fear of another ae) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: The subject can't visit the hospital anymore | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Completed treatment but missed week 144 visit | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance-pi early terminated the subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W/Q8W | Cohort A: BKZ 320 mg Q4W | Cohort A: Group A BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q4W/Q8W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 226 | 51 | 41 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 216 | 49 | 39 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 10 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Consent withdrawn | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Pt cannot commit to study schedule | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
The number of TEAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W | Cohort A: Group A BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q4W/Q8W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total |
|---|---|---|---|---|---|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP) | 97.83 (91.73 to 104.22) | 179.68 (166.62 to 193.49) | 79.02 (65.97 to 93.89) | 77.11 (51.64 to 110.74) | 73.78 (47.75 to 108.92) | 244.08 (178.03 to 326.60) | 328.25 (163.86 to 587.33) | 188.71 (86.29 to 358.22) |
The number of SAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk is used.
| no. of new events per 100 subject-years | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W | Cohort A: Group A BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q4W/Q8W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total |
|---|---|---|---|---|---|---|---|---|
| Number of Serious Adverse Events (SAEs) Adjusted by Duration of Subject Exposure to IMP | 5.24 (4.36 to 6.25) | 6.72 (5.19 to 8.56) | 4.44 (2.22 to 7.95) | 9.05 (2.94 to 21.13) | 8.93 (2.43 to 22.86) | 5.86 (2.36 to 12.08) | 19.51 (6.34 to 45.54) | 7.56 (0.92 to 27.32) |
The number of TEAEs leading to withdrawal adjusted by duration of exposure to study treatment were scaled such that it provided an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to the first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
| no. of new events per 100 subject-years | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W | Cohort A: Group A BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q4W/Q8W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total |
|---|---|---|---|---|---|---|---|---|
| Number of TEAEs Leading to Withdrawal Adjusted by Duration of Subject Exposure to IMP | 2.11 (1.57 to 2.76) | 2.59 (1.69 to 3.80) | 0.79 (0.10 to 2.86) | 1.77 (0.04 to 9.86) | 4.37 (0.53 to 15.79) | 2.42 (0.50 to 7.08) | 3.27 (0.08 to 18.19) | 7.68 (0.93 to 27.74) |
The PASI90 response assessments were based on improvement (reduction) of at least 90% in the PASI score compared to Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
| percentage of participants | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W/Q8W | Cohort A: BKZ 320mg Q4W | Cohort B: PSO BKZ Total |
|---|---|---|---|---|
| Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Non-responder Imputation) | 77.6 | 80.2 | 0 | 73.3 |
PASI90 response assessments were based on improvement (reduction) of at least 90% in the PASI score compared to Baseline. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of the 4 body areas with score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum score is 0= no disease, maximum score is 72= maximal disease.
| percentage of participants | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total |
|---|---|---|
| Psoriasis Area Severity Index 90 (PASI90) Response at Week 144 (Observed Case) | 90.0 | 85.7 |
The Investigator assessed the overall severity of psoriasis using the following 5-point scale: 0 = Clear (no signs of psoriasis; post-inflammatory hyperpigmentation may be present); 1= Almost clear (no thickening; normal to pink coloration; no to minimal focal scaling); 2= Mild (just detectable to mild thickening; pink to light red coloration; predominately fine scaling); 3= Moderate (clearly distinguishable to moderate thickening; dull to bright red coloration; moderate scaling); 4= Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). IGA response -IGA score of clear \[0\] or almost clear \[1\] with at least two category improvement from Baseline at visit timepoint.
| percentage of participants | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W/Q8W | Cohort A: BKZ 320 mg Q4W | Cohort B: PSO BKZ Total |
|---|---|---|---|---|
| Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Non-responder Imputation) | 76.8 | 79.0 | 0 | 60.0 |
The Investigator assessed the overall severity of psoriasis using the following 5-point scale: 0 = Clear (no signs of psoriasis; post-inflammatory hyperpigmentation may be present); 1= Almost clear (no thickening; normal to pink coloration; no to minimal focal scaling); 2= Mild (just detectable to mild thickening; pink to light red coloration; predominately fine scaling); 3= Moderate (clearly distinguishable to moderate thickening; dull to bright red coloration; moderate scaling); 4= Severe (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions). IGA response -IGA score of 0 or 1 at Week 144.
| percentage of participants | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total |
|---|---|---|
| Investigator´s Global Assessment (IGA) 0/1 Response at Week 144 (Observed Case) | 80.0 | 85.7 |
Collected over From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: BKZ 320 mg Q8W | 9/1,217 (0.7%) | 124/1,217 (10.2%) | 771/1,217 (63.4%) |
| Cohort A: BKZ 320 mg Q4W | 6/903 (0.7%) | 65/903 (7.2%) | 566/903 (62.7%) |
| Cohort A: Group A BKZ 320 mg Q8W | 0/226 (0%) | 11/226 (4.9%) | 97/226 (42.9%) |
| Cohort A: Group B BKZ 320 mg Q8W | 0/51 (0%) | 5/51 (9.8%) | 16/51 (31.4%) |
| Cohort A: Group B BKZ 320 mg Q4W/Q8W | 0/41 (0%) | 4/41 (9.8%) | 21/41 (51.2%) |
| Cohort B: PSO BKZ Total | 0/45 (0%) | 7/45 (15.6%) | 43/45 (95.6%) |
| Cohort B: EP BKZ Total | 0/11 (0%) | 5/11 (45.5%) | 11/11 (100%) |
| Cohort B: GPP BKZ Total | 0/10 (0%) | 2/10 (20%) | 9/10 (90%) |
| Event | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W | Cohort A: Group A BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q4W/Q8W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total |
|---|---|---|---|---|---|---|---|---|
| Drug-induced liver injuryHepatobiliary disorders | 0/1217 | 0/903 | 0/226 | 0/51 | 0/41 | 1/45 | 0/11 | 1/10 |
| Autoimmune hepatitisHepatobiliary disorders | 0/1217 | 0/903 | 0/226 | 0/51 | 0/41 | 0/45 | 0/11 | 1/10 |
| Pustular psoriasisSkin and subcutaneous tissue disorders | 0/1217 | 0/903 | 0/226 | 0/51 | 0/41 | 0/45 | 0/11 | 1/10 |
| Cardiac failure congestiveCardiac disorders | 1/1217 | 1/903 | 1/226 | 0/51 | 0/41 | 0/45 | 1/11 | 0/10 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/1217 | 1/903 | 0/226 | 0/51 | 0/41 | 0/45 | 1/11 | 0/10 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 1/1217 | 0/903 | 0/226 | 0/51 | 0/41 | 0/45 | 1/11 | 0/10 |
| Ventricular tachycardiaCardiac disorders | 0/1217 | 0/903 | 0/226 | 0/51 | 0/41 | 0/45 | 1/11 | 0/10 |
| Oedema peripheralGeneral disorders | 0/1217 | 0/903 | 0/226 | 0/51 | 0/41 | 0/45 | 1/11 | 0/10 |
| Pneumonia bacterialInfections and infestations | 0/1217 | 0/903 | 0/226 | 0/51 | 0/41 | 0/45 | 1/11 | 0/10 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/1217 | 0/903 | 0/226 | 0/51 | 0/41 | 0/45 | 1/11 | 0/10 |
| Event | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W | Cohort A: Group A BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q8W | Cohort A: Group B BKZ 320 mg Q4W/Q8W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 152/1217 | 174/903 | 14/226 | 1/51 | 1/41 | 19/45 | 7/11 | 2/10 |
| Oral candidiasisInfections and infestations | 127/1217 | 145/903 | 13/226 | 3/51 | 6/41 | 11/45 | 4/11 | 2/10 |
| EczemaSkin and subcutaneous tissue disorders | 30/1217 | 17/903 | 1/226 | 0/51 | 0/41 | 15/45 | 3/11 | 0/10 |
| PyrexiaGeneral disorders | 25/1217 | 8/903 | 3/226 | 0/51 | 0/41 | 10/45 | 1/11 | 3/10 |
| DiarrhoeaGastrointestinal disorders | 24/1217 | 19/903 | 2/226 | 0/51 | 0/41 | 7/45 | 0/11 | 2/10 |
| Chronic gastritisGastrointestinal disorders | 2/1217 | 3/903 | 0/226 | 0/51 | 0/41 | 2/45 | 0/11 | 2/10 |
| Alanine aminotransferase increasedInvestigations | 9/1217 | 5/903 | 0/226 | 0/51 | 0/41 | 1/45 | 0/11 | 2/10 |
| AcneSkin and subcutaneous tissue disorders | 9/1217 | 9/903 | 0/226 | 0/51 | 0/41 | 2/45 | 0/11 | 2/10 |
| Corona virus infectionInfections and infestations | 174/1217 | 18/903 | 34/226 | 3/51 | 8/41 | 0/45 | 0/11 | 0/10 |
| VertigoEar and labyrinth disorders | 5/1217 | 7/903 | 0/226 | 0/51 | 0/41 | 0/45 | 2/11 | 0/10 |
Baseline Characteristics refer to the Cohort A Safety Set (CA-SS) which consisted of all Cohort A study participants who received at least 1 dose of the investigational medicinal product (IMP) in this study and Cohort B Safety Set (CB-SS) which consisted of all Cohort B study participants in the Cohort B Enrolled Set (CB-ES) who received at least 1 dose of IMP in PS0014 study.
| Age, Continuous(years) | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W/Q8W | Cohort A: BKZ 320 mg Q4W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total | Total |
|---|---|---|---|---|---|---|---|
| Mean | 45.3 ± 13.7 | 45.5 ± 13.2 | 45.4 ± 13.4 | 48.8 ± 11.5 | 55.3 ± 11.9 | 46.0 ± 12.5 | 45.6 ± 13.3 |
| Age, Customized(Participants) | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W/Q8W | Cohort A: BKZ 320 mg Q4W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total | Total |
|---|---|---|---|---|---|---|---|
| 18 - <65 years | 349 | 757 | 68 | 42 | 10 | 10 | 1236 |
| 65 - <85 years | 35 | 76 | 2 | 3 | 1 | 0 | 117 |
| >= 85 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W/Q8W | Cohort A: BKZ 320 mg Q4W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total | Total |
|---|---|---|---|---|---|---|---|
| Female | 118 | 221 | 24 | 9 | 0 | 4 | 376 |
| Male | 266 | 612 | 46 | 36 | 11 | 6 | 977 |
| Race/Ethnicity, Customized(Participants) | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W/Q8W | Cohort A: BKZ 320 mg Q4W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total | Total |
|---|---|---|---|---|---|---|---|
| American Indian/Alaskan Native | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Asian | 31 | 107 | 8 | 45 | 11 | 10 | 212 |
| Black | 1 | 14 | 2 | 0 | 0 | 0 | 17 |
| Native Hawaiian or Other Pacific Islander | 2 | 2 | 0 | 0 | 0 | 0 | 4 |
| White | 344 | 695 | 58 | 0 | 0 | 0 | 1097 |
| Other/mixed | 5 | 14 | 2 | 0 | 0 | 0 | 21 |
| Race/Ethnicity, Customized(Participants) | Cohort A: BKZ 320 mg Q8W | Cohort A: BKZ 320 mg Q4W/Q8W | Cohort A: BKZ 320 mg Q4W | Cohort B: PSO BKZ Total | Cohort B: EP BKZ Total | Cohort B: GPP BKZ Total | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 20 | 40 | 11 | 0 | 0 | 0 | 71 |
| Not Hispanic or Latino | 364 | 793 | 59 | 45 | 11 | 10 | 1282 |
Showing the first 100 of 189 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Sep 2018 to primary completion in Nov 2023, 62 months.
Results were first posted in Dec 2024, 1 year after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 62 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab